—OCT results demonstrate effective treatment of a broad range of complex calcified lesions, including concentric and eccentric calcium and lesions with calcium nodules— “The cardiology community has ...

MILPITAS, Calif. , Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced key milestone and full market release of ...

LithiX™ HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques MY-IVL study enrolled 102 real ...

First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea. Novel IVL technology designed to deliver calcium ...

WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced positive six-month data from the PINNACLE I study evaluating the ...

MILPITAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced EU MDR CE Mark approval and commercial ...

MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz ...

MILPITAS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, announced results from the MY-IVL Study at the Transcatheter ...

Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an energy source. IVL technology expands ...